Tamoxifen induces fatty liver disease in breast cancer through the MAPK8/FoxO pathway.

ABSTRACT:

Background

Prevention of metabolic complications of long-term adjuvant endocrine therapy in breast cancers remained a challenge. We aimed to investigate the molecular mechanism in the development of tamoxifen (TAM)-induced fatty liver in both estrogen receptor (ER)-positive and ER-negative breast cancer.

Methods and results

First, the direct protein targets (DPTs) of TAM were identified using DrugBank5.1.7. We found that mitogen-activated protein kinase 8 (MAPK8) was one DPT of TAM. We identified significant genes in breast cancer and fatty liver disease (FLD) using the MalaCards human disease database. Next, we analyzed the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of those significant genes in breast cancer and FLD using the Search Tool for the Retrieval of I

SUBMITTER: Gong L 

PROVIDER: S-EPMC7240857 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature